ProQR Therapeutics N.V.
PRQRNASDAQHealthcare● Active
$1.53
+$0.03(+2.00%)
Market Cap$161202330
P/E Ratio—
52W High$3.1
52W Low$1.33
ProQR Therapeutics N.V. (PRQR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRQR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $15.28M | $18.91M | $6.51M | $3.59M | $1.33M |
| Cost of Revenue | $2.60M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $12.68M | $18.91M | $6.51M | $3.59M | $1.33M |
| Gross Margin %(computed) | 83.01% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $40.72M | $36.36M | $25.15M | $50.87M | $42.22M |
| G&A Expenses | $0.00M | $13.66M | $16.24M | $18.65M | $17.37M |
| Total Operating Expenses | $54.84M | $49.38M | $38.37M | $68.75M | $58.55M |
| Operating Income | ($42.15M) | ($30.47M) | ($31.86M) | ($65.16M) | ($57.21M) |
| Operating Margin %(computed) | -275.91% | -161.18% | -489.09% | — | — |
| Interest Income | $2.24M | $3.25M | $2.59M | $0.11M | $0.01M |
| Interest Expense | $0.87M | $1.08M | $1.20M | $5.13M | $3.40M |
| Income Before Tax | ($40.50M) | ($27.96M) | ($27.81M) | ($64.11M) | ($60.68M) |
| Income Tax Expense | $0.02M | ($0.20M) | ($0.08M) | $0.10M | $0.12M |
| Net Income | ($40.52M) | ($27.76M) | ($28.12M) | ($64.42M) | ($60.74M) |
| Net Margin %(computed) | -265.21% | -146.86% | -431.67% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.38 | $-0.34 | $-0.35 | $-0.91 | $-0.96 |
| Wtd Avg Shares | 105.33M | 81.67M | 81.01M | 71.64M | 64.18M |
| EBITDA | ($39.56M) | ($24.12M) | ($24.10M) | ($56.46M) | ($54.95M) |
| EBITDA Margin %(computed) | -258.92% | -127.60% | -369.93% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · EUR · M
Explore more ProQR Therapeutics N.V. data
About ProQR Therapeutics N.V. (PRQR) Income Statement
ProQR Therapeutics N.V. (PRQR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PRQR reported revenue of $0.02B, gross profit of $0.01B (gross margin 83.01%), and net income of ($0.04B) — a net profit margin of -265.21%.
Frequently asked questions
PRQR · 4 questionsProQR Therapeutics N.V. (PRQR) reported revenue of $0.02B for 2025, down 19.2% year-over-year.
PRQR revenuePRQR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08